{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:00:03Z","timestamp":1759341603559},"reference-count":31,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            With increasing resistance to existing antimalarials, there is an urgent need to discover new drugs at affordable prices for countries in which malaria is endemic. One approach to the development of new antimalarial drugs is to improve upon existing antimalarial agents, such as the tetracyclines. Tetracyclines exhibit potent, albeit relatively slow, action against malaria parasites, and doxycycline is used for both treatment (with other agents) and prevention of malaria. We synthesized 18 novel 7-position modified tetracycline derivatives and screened them for activity against cultured malaria parasites. Compounds with potent\n            <jats:italic>in vitro<\/jats:italic>\n            activity and other favorable drug properties were further tested in a rodent malaria model. Ten compounds inhibited the development of cultured\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium falciparum<\/jats:named-content>\n            with a 50% inhibitory concentration (IC\n            <jats:sub>50<\/jats:sub>\n            ) after 96 h of incubation of &lt;30 nM, demonstrating activity markedly superior to that of doxycycline (IC\n            <jats:sub>50<\/jats:sub>\n            at 96 h of 320 nM). Most compounds showed little mammalian cell cytotoxicity and no evidence of\n            <jats:italic>in vitro<\/jats:italic>\n            phototoxicity. In a murine\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Plasmodium berghei<\/jats:named-content>\n            model, 13 compounds demonstrated improved activity relative to that of doxycycline. In summary, 7-position modified tetracyclines offer improved activity against malaria parasites compared to doxycycline. Optimized compounds may allow lower doses for treatment and chemoprophylaxis. If safety margins are adequate, dosing in children, the group at greatest risk for malaria in countries in which it is endemic, may be feasible.\n          <\/jats:p>","DOI":"10.1128\/aac.00451-13","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T03:01:41Z","timestamp":1367290901000},"page":"3131-3136","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Antimalarial Efficacies of Optimized Tetracyclines"],"prefix":"10.1128","volume":"57","author":[{"given":"Michael P.","family":"Draper","sequence":"first","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beena","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haregewein","family":"Assefa","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Honeyman","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne K.","family":"Garrity-Ryan","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul K.","family":"Verma","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Gut","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Division of Infectious Diseases, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley","family":"Larson","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Donatelli","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Macone","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Klausner","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raina G.","family":"Leahy","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandrs","family":"Odinecs","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwasi","family":"Ohemeng","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Division of Infectious Diseases, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark L.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2001.64.1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.30875\/ac42f7b8-en"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530270070034"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.181"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808859"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0900231"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.703651"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.21"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1983.32.221"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4894(76)90073-4"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1973.11686870"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1972.03200050026007"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0285"},{"key":"e_1_3_2_15_2","volume-title":"Basic and clinical pharmacology","author":"Rosenthal PJ","year":"2009","unstructured":"RosenthalPJ. 2009. Antiprotozoal drugs. In Basic and clinical pharmacology. Lange Medical Books\/McGraw Hill, New York, NY."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.262-264.2002"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.47.3.567"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199805000-00019"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200009000-00011"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/0009922806290026"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo030047d"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.3.949-951.2001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbiopara.2006.06.013"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7519(00)00035-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00394-06"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(94)90396-4"},{"key":"e_1_3_2_27_2","first-page":"545","volume-title":"Progress in the reduction, refinement and replacement of animal experimentation","author":"Zerler B","year":"2000","unstructured":"ZerlerB RoemerE RaabeH ReevesA SizemoreA HarbellJW. 2000. Evaluation of the phototoxic potential of chemical modified tetracyclines with the 3T3 neutral red uptake phototoxicity test, p 545\u2013554. In BallsM van ZellerA-M HalderM (ed), Progress in the reduction, refinement and replacement of animal experimentation. Elsevier Sciences, Amsterdam, the Netherlands."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03160.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1879"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.23.2603"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1617"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.943-949.2000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00451-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00451-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:33:07Z","timestamp":1645482787000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00451-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/AAC.00451-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00451-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"2013-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}